CBD–Acetaminophen Oral Formulation for Rapid, Sustained Pain Relief

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing oral pain relievers face challenges such as delayed onset of action, gastrointestinal side effects, liver or kidney toxicity, and risks of dependency or abuse, while existing cannabinoid-based formulations have variable effectiveness and side effects due to bioavailability and individual variability.

Innovation Solution

A composition combining cannabidiol isolate and acetaminophen with excipients like starch, sucrose, and polyvinylpyrrolidone, formulated for rapid or controlled release, optimizing drug delivery and efficacy for pain relief.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If traditional oral analgesics (NSAIDs, acetaminophen, ibuprofen, opioids) are used, then pain relief is provided, but delayed onset of action, gastrointestinal side effects, liver or kidney toxicity, and risks of dependency or abuse occur

Engineering Contradiction:

Improvepain relief effectivenessVSAvoidgastrointestinal side effects, liver or kidney toxicity, dependency risk

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent combines cannabidiol isolate with acetaminophen in a single oral composition to leverage the analgesic and anti-inflammatory properties of both substances. This combination aims to provide synergistic pain relief while reducing the dosage requirements of each individual component, thereby minimizing side effects and toxicity risks associated with traditional oral analgesics

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The invention creates a composite pharmaceutical formulation containing cannabidiol isolate and acetaminophen in specific ratios (2-35% CBD and 65-98% acetaminophen by dry weight). This composite material approach allows for optimized drug delivery characteristics and enhanced therapeutic effects while reducing harmful side effects compared to conventional single-ingredient analgesics

Inventive Principle:

Principle #40Composite materials

2Reliability

If cannabinoid-based formulations are used, then pain relief effects are achieved, but variable effectiveness and side effects occur due to bioavailability and individual variability

Engineering Contradiction:

Improvepain relief effectivenessVSAvoidbioavailability consistency

Core Design Contradiction:

ReliabilityVSStability of the object's composition

Solution Approach 1:

The patent uses highly purified cannabidiol isolate (≥98% purity) extracted from cannabis plant material, removing impurities and other cannabinoids that contribute to variable bioavailability and inconsistent effects. This extraction and purification process ensures standardized, predictable therapeutic outcomes while maintaining the beneficial analgesic properties of cannabidiol

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The invention optimizes the purity parameter of cannabidiol to ≥98% and controls the concentration ratios in the formulation (2-35% CBD, 65-98% acetaminophen by dry weight). These parameter changes standardize the composition to ensure consistent bioavailability and reproducible pain relief effects across different individuals and dosages

Inventive Principle:

Principle #35Parameter changes

3Speed

If rapid release formulation is used, then faster onset of pain relief is achieved, but reduced sustained analgesic effect occurs

Engineering Contradiction:

Improveonset of actionVSAvoidsustained analgesic effect

Core Design Contradiction:

SpeedVSDuration of action of moving object

Solution Approach 1:

The patent divides the analgesic effect into two components: rapid-acting cannabidiol isolate for quick onset of pain relief and sustained-acting acetaminophen for prolonged analgesic effect. This segmentation of functional roles allows the formulation to achieve both fast onset and sustained duration of action simultaneously

Inventive Principle:

Principle #1Segmentation

4Duration of action of moving object

If higher dosage of traditional analgesics is used to achieve sustained pain relief, then duration of action is extended, but side effects and toxicity risks increase

Engineering Contradiction:

Improvesustained analgesic effectVSAvoidliver or kidney toxicity, gastrointestinal side effects

Core Design Contradiction:

Duration of action of moving objectVSObject-affected harmful factors

Solution Approach 1:

The patent combines cannabidiol isolate with acetaminophen in optimized ratios to achieve sustained analgesic effects at lower total dosages. The synergistic interaction between the two active ingredients allows for reduced dosage requirements compared to using acetaminophen alone, thereby extending duration of action while minimizing liver toxicity and gastrointestinal side effects

Inventive Principle:

Principle #5Merging (Combining)

Data Source

PatentUS20250302778A1Oral pain reliever composition, pharmaceutical formulation, and process for making composition and formulation including cannabidiol isolate with select active ingredients

Publication Date: 2025.10.02 CAVENDER MICHAEL

AI summary

A chemical composition for an oral pharmaceutical product is described having a therapeutically effective amount of one or more active pharmaceutical ingredients (API) including acetaminophen in combination with a cannabidiol (CBD) isolate.